Primer aislamiento de Candida auris en el Laboratorio Clínico del Hospital México, Costa Rica
Autores
Ariel Miranda Padilla, Bayron González Solórzano, Yósselin Morales Rodríguez
Resumen
Candida auris es un patógeno emergente que ha incrementado su relevancia en los últimos
años en el ámbito de la salud pública mundial debido a su alta resistencia a antifúngicos
tradicionales. Este se trata del segundo aislamiento de Candida auris en Costa Rica y el
primer reporte a nivel clínico en el Hospital México. La cepa provino de una muestra de
líquido peritoneal aislada de un paciente extranjero hospitalizado, con antecedentes de
complicaciones gastrointestinales y varias consultas médicas previas. El laboratorio clínico
realizó una identificación oportuna de la cepa; se realizaron las respectivas pruebas
confirmatorias y análisis de sensibilidad. Se emitió la alerta epidemiológica por parte del
Ministerio de Salud de Costa Rica y se informaron las medidas sanitarias y preventivas
correspondientes para estos casos emergentes. Se hace énfasis en la importancia de mantener
adecuados protocolos de laboratorio a fin de detectar oportunamente la aparición de esta
levadura.
Palabras clave
Candida auris, antifúngicos, Costa RicaAbstract
Candida auris is an emerging pathogen, which has increased its relevance in recent times
regarding public health, due to its high resistance to traditional antifungals. This is the second
isolation of Candida auris in Costa Rica, and the first clinical report at Hospital México. The strain was isolated from a peritoneal fluid sample of a hospitalized foreign patient, with a
history of gastrointestinal complications, and several previous medical consultations. The
clinical laboratory carried out a timely identification of the strain, the respective confirmatory
tests, and sensitivity analysis were carried out. The epidemiological alert was issued by Costa
Rica’s Ministry of Health; sanitary and preventive measures were reported in the face of these
emerging cases. Emphasis is placed on the importance of maintaining adequate laboratory
protocols in order to timely detect the appearance of this yeast.
Key words
Candida auris, antifungals, Costa Rica.Texto completo
Referencias
1. Sanyaolu A, Okorie C, Marinkovic A, Abbasi AF, Prakash S, Mangat J, et al.
Candida auris: An Overview of the Emerging Drug-Resistant Fungal Infection.
Infect Chemother. 2022;54(2):236.
2. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida
auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an
inpatient in a Japanese hospital. Microbiology and Immunology. 2009;53(1):41-4
3. Oh M, Heyl J, Babu MBA BA. Candida auris in the Age of Resistance. Cureus.
2020; 12(9): e10334.
4. Calvo B, Melo ASA, Perozo-Mena A, Hernández M, Francisco EC, Hagen F, et al.
First report of Candida auris in America: Clinical and microbiological aspects of 18
episodes of candidemia. Journal of Infection. 2016;73(4):369-74.
5. Chow NA, Muñoz JF, Gade L, Berkow EL, Li X, Welsh RM, et al. Tracing the
Evolutionary History and Global Expansion of Candida auris Using Population
Genomic Analyses. mBio. 2020;11(2):e03364-19.
6. Center for Disease Control and Prevention (CDC). Increasing Threat of Spread of
Antimicrobial-resistant Fungus in Healthcare Facilities. [Internet]. 20 marzo, 2023
[Consultado 21 de marzo 2023]. Disponible en:
https://www.cdc.gov/media/releases/2023/p0320-cauris.html
7. Ávalos A. Abuso de antibióticos abre las puertas a los supergérmenes. La nación
[Internet]. 21 de julio de 2019 [Consultado 20 de mayo 2023]. Recuperado a partir
de: https://www.nacion.com/el-pais/salud/abuso-de-antibioticos-en-personasanimales-y/BWIP5FT52NGGPKDKJRSMFSLZHU/story/
8. Paucar-Miranda, CJ, Sandoval-Ahumada, RE, López-Martínez, RL, TerrelGutierrez, L, Zurita-Macalapu, S, Urcia-Ausejo, F, Yagui-Moscoso, M. Primer
reporte de prensa que Candida auris en Perú. Anales de la Facultad de Medicina.
UNMSM. Facultad de Medicina. 2021; 82 (1): 56-61
9. OPS/OMS. Alerta Epidemiológica: Brotes de Candida auris en servicios de atención
a la salud. Organización Panamericana de la Salud. [Internet]. 03 octubre, 2016
[Consultado 12 de mayo 2023]. Disponible en:
https://www.paho.org/hq/dmdocuments/2016/2016-oct-3-phe-alerta-epi-candidaauris.pdf
10. Center for Disease Control and Prevention (CDC). Algorithm to identify Candida
auris based on phenotypic laboratory method and initial species identification.
[Internet]. 17 mayo, 2019 [Consultado 04 de abril 2023]. Disponible en:
https://www.cdc.gov/fungal/diseases/candidiasis/pdf/Testing-algorithm-by-Methodtemp.pdf.
11. Leber, Amy L, editor. Clinical Microbiology Procedures Handbook. 4ta ed.,
American Society for Microbiology Press, 2016.
12. Gross N, Salas I. Métodos diagnósticos en Micología Médica. 1ed. San José: UCR
Edit; 2015.
13. CLSI. Performance Standards for Antifungal Susceptibility Testing of Yeast. 3era ed.
CLSI supplement M27M44S. Clinical and Laboratory Standards Institute; 2022.
14. Center for Disease Control and Prevention (CDC). Tracking Candida auris.
[Internet]. 13 enero, 2021 [Consultado 04 de abril 2023]. Disponible en:
https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html.
15. Watkins RR, Gowen R, Lionakis M, Ghannoum M. Update on the Pathogenesis,
Virulence, and Treatment of Candida auris. PAI. 2022;7(2):46-65.
16. Garcia-Bustos V, Cabañero-Navalon MD, Ruiz-Gaitán A, Salavert M, Tormo-Mas
MÁ, Pemán J. Climate change, animals, and Candida auris: insights into the
ecological niche of a new species from a One Health approach. Clinical
Microbiology and Infection. 2023; 29(7):858-862.
17. Chaabane F, Graf A, Jequier L, Coste AT. Review on Antifungal Resistance
Mechanisms in the Emerging Pathogen Candida auris. Front Microbiol. 2019;
10:2788.
18. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A
multicentre study of antifungal susceptibility patterns among 350 Candida auris
isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and
echinocandin resistance. Journal of Antimicrobial Chemotherapy. 2018;73(4):891-
9.
19. Du H, Bing J, Hu T, Ennis CL, Nobile CJ, Huang G. Candida auris: Epidemiology,
biology, antifungal resistance, and virulence. Xue C, editor. PLoS Pathog.
2020;16(10):e1008921.
20. Fayed B, Jayakumar MN, Soliman SSM. Caspofungin-resistance in Candida auris is
cell wall-dependent phenotype and potential prevention by zinc oxide nanoparticles.
Medical Mycology. 2021;59(12):1243-56.
21. Jacobs SE, Jacobs JL, Dennis EK, Taimur S, Rana M, Patel D, et al. Candida auris
Pan-Drug-Resistant to Four Classes of Antifungal Agents. Antimicrob Agents
Chemother. 2022;66(7):e00053-22.
22. Lepak AJ, Zhao M, Berkow EL, Lockhart SR, Andes DR. Pharmacodynamic
Optimization for Treatment of Invasive Candida auris Infection. Antimicrob Agents
Chemother. 2017;61(8): e00791-17.
23. Zerrouki H, Ibrahim A, Rebiahi S, Elhabiri Y, Benhaddouche D, de Groot T, et al.
Emergence of Candida auris in intensive care units in Algeria. Mycoses.
2022;65(7):753-9.
24. Vila T, Montelongo-Jauregui D, Ahmed H, Puthran T, Sultan AS, Jabra-Rizk MA.
Comparative Evaluations of the Pathogenesis of Candida auris Phenotypes and
Candida albicans Using Clinically Relevant Murine Models of Infections. Mitchell
AP, editor. mSphere. 2020;5(4): e00760-20.
25. OPS/OMS. Alerta Epidemiológica: Brotes de Candida auris en servicios de atención
a la salud en el contexto de la pandemia de COVID-19. Organización Panamericana
de la Salud. [Internet]. 06 febrero, 2021 [Consultado 12 de mayo 2023].
Disponible en: https://iris.paho.org/bitstream/handle/10665.2/53377/EpiUpdate6February2021_spa.pdf?sequence=2&isAllowed=y.